IMPORTANCE Guidelines recommend measuring preoperative carcinoembryonic antigen (CEA) in patients with colon cancer. Although persistently elevated CEA after surgery has been associated with increased risk for metastatic disease, prognostic significance of elevated preoperative CEA that normalized after resection is unknown.
F irst described in 1965, carcinoembryonic antigen (CEA) is a colorectal cancer tumor marker [1] [2] [3] [4] [5] [6] that the National
Comprehensive Cancer Network, the American Society of Clinical Oncology, and the European Group on Tumour Markers recommend be measured preoperatively in patients with nonmetastatic colorectal cancer.
7-9 Elevated CEA levels are associated with metastases and recurrence, and some investigators have suggested that it be included in the American Joint Committee on Cancer staging system. 4, 5, [10] [11] [12] Before widespread use of modern imaging, an elevated preoperative CEA prompted additional investigation, such as liver scintigraphy, to search for metastases. 13 In the era of highquality computed tomography (CT), the utility of measuring preoperative CEA is less obvious because an elevated preoperative CEA with a normal CT scan does not preclude surgery with curative intent. An elevated preoperative CEA can normalize after resection of the primary tumor. [14] [15] [16] [17] In this study we sought to determine whether preoperative or postoperative CEA is more prognostic. Specifically, we asked whether patients with elevated preoperative CEA that normalizes after resection of the primary tumor had a risk of recurrence similar to that of patients with normal preoperative CEA.
Methods

Study Design and Patient Cohort
With institutional review board approval and a waiver of the requirement for patient consent, prospectively maintained databases were queried for all consecutive patients who underwent curative resection for stage I to III colon adenocarcinoma from January 2007 through December 2014 at Memorial Sloan Kettering Cancer Center. The exclusion criteria were treatment for malignancy within the last 5 years, preoperative chemotherapy or radiotherapy, noncurative palliative resection, and lack of preoperative CEA data. Data on patient demographics, perioperative clinical outcomes, pathologic outcomes, and disease status at last follow-up were collected from the database, and the electronic medical record was reviewed. Tumor location was categorized as right colon (cecum, ascending, and transverse colon) or left colon (descending, sigmoid, and rectosigmoid colon). Preoperative CEA was defined as the CEA value closest to the time of surgery, and postoperative CEA was defined as the last CEA value within 12 weeks after surgery and before starting adjuvant chemotherapy. Patients were grouped by CEA status as follows: (1) patients with normal (≤5.0 ng/mL [to convert to μg/L, multiply by 1.0]) preoperative CEA (normal preoperative group); (2) patients with elevated (>5.0 ng/mL) preoperative CEA but normal postoperative CEA (normalized postoperative group); and (3) patients whose preoperative and postoperative CEA levels were both elevated (elevated postoperative group). The CEA assay was performed at Memorial Sloan Kettering using a Tosoh AIA-2000 automated analyzer (Tosoh Bioscience, Inc). The reference range for the assay was 0.0 to 5.0 ng/mL.
Staging and Surveillance Protocol
Preoperative staging included colonoscopy and contrastenhanced CT of the chest, abdomen, and pelvis. Adjuvant chemotherapy was administered to patients with stage III or high-risk stage II disease after histological evaluation of the surgical specimen as recommended in national guidelines. [7] [8] [9] 18 The general practice for postoperative surveillance of stage I to III colon cancer at Memorial Sloan Kettering (in accordance with national guidelines [7] [8] [9] 18 ) included physical examination, interval history, and serum CEA testing at 3-to 6-month intervals for the first 2 to 3 years and at 6-month intervals thereafter for 5 years. Imaging, most frequently CT of the chest, abdomen, and pelvis with oral and intravenous contrast, was performed at a minimum of every 12 months for at least 3 years. Colonoscopy was typically performed at 1 year after surgery and then repeated every 3 to 5 years unless advanced adenomas were identified. Radiographic reports were reviewed, and a definitive diagnosis of recurrence was based on the appearance of new lesions on CT, magnetic resonance imaging (MRI), and/or positron emission tomography (PET) images and/or histological confirmation through biopsy.
Statistical Analysis
Continuous variables were compared using the MannWhitney U test. Categorical variables were compared using the χ 2 test. Recurrence-free survival (RFS) was estimated using the Kaplan-Meier method. Recurrence-free survival time was calculated from the date of surgery until the date of recurrence, death, or last follow-up. Death and disease recurrence were treated as events in the analysis. Patients who were alive without recurrence at last follow-up were censored. Differences in RFS were assessed by the log-rank test (univariate analysis). Hazard ratios (HRs) and 95% CIs were estimated using Cox regression models and assessed by the Wald test. Association with RFS was evaluated by multivariable Cox regression. Variables with P values of less than .05 on univariate analysis were included in the final multivariable model. The hazard function of recurrence or death was plotted using the kernelsmoothing method. 19, 20 All statistical analyses were performed using JMP version 10. Patients were excluded if they had prior cancer treatment within 5 years (n = 134), preoperative chemotherapy or radiotherapy (n = 17), noncurative palliative resection (n = 2), or missing preoperative CEA (n = 68). Among the remaining 1027 patients, preoperative CEA was normal in 715 patients (69.6%) and elevated in 312 patients (30.4%). Of the 312 patients with elevated preoperative CEA, 199 had postoperative CEA data available; 142 of these patients had normalized postoperative CEA levels and 57 had elevated postoperative CEA levels ( Figure 1 ). Descriptive statistics for the 914 patients with either normal preoperative CEA or elevated preoperative CEA with evaluable postoperative CEA are shown in eTable 1 in the Supplement. Tumors were located in the right colon in 468 patients (51.2%) and in the left colon in 446 patients (48.8%). Median (IQR) preoperative and postoperative CEA levels were 2.8 (1.9-4.6) ng/mL and 2.5 (1.7-3.7) ng/mL, respectively. Median (IQR) interval from surgery to postoperative CEA testing was 35 (26-49) days. Median (IQR) follow-up was 38 (21-56) months. A total of 94 patients (10.3%) had recurrences, and 42 patients (4.6%) died before the last follow-up. The 3-year RFS rate for all patients was 88.4% (95% CI, 85.9%-90.5%).
The 3-year RFS rate for the 312 patients with elevated preoperative CEA was 82.3% (95% CI, 77.1%-86.6%) compared with 89.7% (95% CI, 87.0%-92.0%) for the 715 patients with normal preoperative CEA (HR, 1.68; 95% CI, 1.19-2.39; P = .05) (Figure 2A) . The 3-year RFS was 74.5% (95% CI, 61.4%-84.3%) for the 57 patients whose CEA levels remained elevated after surgery compared with 89.4% (95% CI, 86.9%-91.5%) for the 857 patients with either normal preoperative CEA (n = 715) or normalized postoperative CEA (n = 142) (HR, 2.53; 95% CI, 1.44-4.44; P = .001) ( Figure 2B ). The 3-year RFS for the 142 patients with normalized postoperative CEA was 87.9% (95% CI, 80.8%-92.6%), which was statistically indistinguishable from the 89.7% (95% CI, 87.0%-92.0%) 3-year RFS in the 715 patients who had normal preoperative CEA levels (HR, 1.05; 95% CI, 0.63-1.76; P = .85) ( Figure 2C ). In contrast the 3-year RFS rate of the 57 patients with persistently elevated CEA after surgery was 74.5%, which was significantly lower than that of the other 2 groups (elevated postoperative CEA vs normal preoperative CEA: HR, 2.56; 95% CI, 1.44-4.52; P = .001 and elevated postoperative CEA vs normalized postoperative CEA: HR, 2.43; 95% CI, 1.21-4.89; P = .02) (overall log-rank P = .004) ( Figure 2C ). Repeat analyses using a CEA cutoff of 10.0 ng/mL (rather than 5.0 ng/mL) produced similar results (eFigure 1 in the Supplement).
The smoothed curve of the hazard function for each CEA group indicated that the risk of recurrence was higher and also peaked earlier in the elevated postoperative CEA group ( Figure 2D ). The hazard function curves for the normal preoperative and normalized postoperative CEA groups are indistinguishable, confirming that the risk and timing of recurrence in these 2 groups are similar.
Stage-specific RFS based on CEA is shown in eFigure 2 in the Supplement. In patients with stage I (eFigure 2A in the Supplement) or stage II (eFigure 2B in the Supplement) disease, the RFS of the 3 cohorts (normal preoperative, normalized postoperative, and elevated postoperative CEA) did not differ significantly. However, among patients with stage III disease, the RFS was significantly lower in the elevated postoperative CEA group than in the normal preoperative or normalized postoperative CEA groups (elevated postoperative CEA vs normal preoperative CEA: HR, 2.78; 95% CI, 1.44-5.38; P = .002 and elevated postoperative CEA vs normalized postoperative CEA: HR, 4.37; 95% CI, 1.81-10.58; P = .002) (overall log-rank P = .001) (eFigure 2C in the Supplement).
Univariate and multivariate analyses of factors associa t edwi thRF Sar esho wnineT able2intheSupplement.In No association was noted between normal or elevated perioperative CEA and site of initial recurrence (eTable 3 in the Supplement).
Discussion
Consistent with the literature, 15,16,21,22 our data show that postoperative CEA is more informative than preoperative CEA. Patients with an elevated preoperative CEA had an absolute 7.4% lower 3-year RFS than those with normal preoperative CEA. However, CEA normalized in more than 70% of patients following surgery, and the outcome of patients with normalized postoperative CEA is similar to that of patients with normal preoperative CEA. Conversely, those patients with persistently elevated CEA following surgery had an absolute 14.9% lower 3-year RFS than those with either normal preoperative CEA or normalized postoperative CEA. The impact of elevated postoperative CEA is further demonstrated in a review of the hazard function curves over time ( Figure 2D ), which show an earlier and higher hazard rate peak in the elevated postoperative CEA cohort compared with normal preoperative and normalized postoperative groups. Multivariate modeling also confirms that elevated postoperative CEA was more prognostic than elevated preoperative CEA. When evaluating the results by stage, it is clear that postoperative CEA is able to stratify patients with stage III disease rather than stage I and II, likely because of limited recurrence in the latter groups, with 3-year disease-free survival greater than 98% and 91% for stage I and II, respectively. These findings suggest that with regard to prognosis, measuring postoperative rather than preoperative CEA is more instructive. Elevated preoperative CEA is not informative when postoperative CEA is normal. Can preoperative CEA measurements be eliminated? Does CEA assist in identifying metastatic disease? It is unlikely that CEA is of great use in identifying metastatic disease in the setting of modern imaging. Clinically, patients with an elevated preoperative CEA and an otherwise normal contrast-enhanced CT of the chest, abdomen, and pelvis proceed to surgery with the assumption that the primary lesion is the source of the elevated CEA. Some may argue that an elevated preoperative CEA is a useful marker in follow-up. 9 That is, clinicians are more likely to assume a rise in CEA is the result of metastases if the patient had an elevated preoperative CEA. However, recurrence can be accompanied by normal or elevated CEA irrespective of preoperative CEA. Our results indicate that postoperative CEA may inform frequency of surveillance. Patients with elevated postoperative CEA have a hazard function that rises quickly and peaks within 12 months before declining to meet that of patients with normal preoperative CEA or normalized postoperative CEA. This may support using postoperative CEA to stratify patients for graded surveillance as outlined by the National Comprehensive Cancer Network. However, we cannot conclude from this data set if additional immediate imaging, such as MRI, ultrasound, or 18 F-fluorodeoxyglucose PET and CT, would be beneficial in patients with postoperative elevation in CEA. Often, a short interval follow-up CT scan is performed. Although some studies 15, 17 have found that disease recurrence in patients with colorectal cancer and elevated preoperative or postoperative CEA is more common in the liver than at other sites, we did not find a significant difference among sites in the likelihood of recurrence. The major strengths of this study include the large size of the cohort of patients staged with high-quality preoperative CT; the uniform treatment patients received, with complete mesocolic excision technique by specialized colorectal surgeons at a high-volume comprehensive cancer center; and the use of a standard chemotherapy regimen in all patients. Unlike past studies, routine use of high-quality CT scan very likely improved staging by enabling identification of lowvolume metastases that may have been undetectable with older imaging technology. Furthermore, improved nodal clearance with complete mesocolic excision technique optimizes tumor resection and nodal staging. Oncological outcomes in this study were similar to those seen in other reports of complete mesocolic excision, confirming that the cohort is a representative sample of stage I to III colon cancer in the era of complete mesocolic excision and modern preoperative imaging. 28 We do not know if the results can be applied to centers that do not perform high-quality preoperative CT scans or complete mesocolic excisions. Confirmatory studies would be necessary.
Limitations
The analysis is subject to the limitations and bias inherent in observational retrospective studies. For example, postoperative CEA data were not available for 113 patients with elevated preoperative CEA. Patients who had postoperative CEA measured were more likely to have stage III disease (43% vs 29%; P = .002), suggesting that the patients with a higher risk had postoperative CEA testing. Timing of postoperative CEA measurement was not controlled, although it was limited to within 12 weeks after surgery and before starting adjuvant chemotherapy. Care was taken to allow sufficient time following surgery before measuring CEA (IQR, 26-49 days) to allow CEA normalization (the half-life of CEA is 3-7 days.) 25 We did not evaluate optimal CEA cutoff but did find similar results when using 5 and 10 ng/mL cutoff values. Postoperative surveillance was in accordance with national guidelines; however, in this retrospective study, intervals and completeness of the follow-up undoubtedly varied. That being said, the hazard function curve ( Figure 2D ) showed an earlier peak of recurrence in the elevated postoperative CEA cohort (3.8 months) compared with normal preoperative CEA (16.4 months) and Multiple studies have demonstrated that elevated preoperative CEA is associated with worse survival in patients with earlystage disease (stages I-III) independent of tumor stage. For this reason, the American Joint Committee on Cancer has proposed adding preoperative CEA level (C-stage) to TNM staging.
3
In addition, lack of CEA normalization after resection is associated with residual occult disease. It is often assumed that the value of CEA in surveillance is restricted to patients who have elevated serum levels at baseline, thus supporting preoperative assessment. The work by Konishi et al 4 in this issue of JAMA Oncology raises intriguing questions about the timing of CEA measurement as a prognostic marker for early colon cancer. The authors explored whether postoperative CEA levels were more informative than preoperative levels. They conducted a retrospective cohort study of 1027 patients with stage I to III colon cancer who underwent curative resection at a single National Cancer Institute-designated comprehensive cancer center between January 2007 and December 2014 and who had a preoperative CEA result available. The primary end point was recurrence at 3 years. Preoperative CEA performed as anticipated: patients with normal levels had a 7.4% higher 3-year recurrence-free survival (RFS) than those with elevated levels (89.7% vs 82.3%; P = .01). Notably, the adverse prognostic impact of elevated preoperative CEA was negated in those patients whose CEA normalized in the postoperative period. Patients with normal postoperative CEA, regardless of preoperative level, had a 14.9% higher 3-year RFS than those with elevated postoperative CEA (89.4% vs 74.5%; P = .001). In addition, among patients with normal baseline CEA levels who ultimately experienced recurrence, 38% had elevated CEA at the time of recurrence. The authors therefore suggest that routine measurement of postoperative, rather than preoperative, CEA is warranted. Interestingly, patients with high postoperative CEA also experienced earlier recurrence than patients who had normal baseline or postoperative CEA level. This study highlights the potential of real-world evidence to contribute insights that might ultimately lead to changes in clinical guidelines and standards of care. Real-world evidence is based on real-world data obtained during the conduct of routine clinical practice rather than data required in a controlled clinical trial protocol. As noted in a recent position statement of the American Society of Clinical Oncology, 5 such observational data may be complementary to evidence obtained from randomized clinical trials. Although observational studies may lack a randomized control group and rigorous prespecified data collection, the real-world data they produce may be more representative of patients and exposures (eg, diagnostics, treatments) in routine practice; therefore, real-world evidence may be more broadly generalizable. The widespread adoption of electronic health records and the establishment of registries for routine collection of treatment and outcome data provide rich resources from which to generate and test clinical hypotheses. However, it is critical that potential biases in such analyses are understood. In assessing new evidence derived from patient experiences in routine clinical settings, it is helpful to explicitly recognize the characteristics of high-quality real-world evidence, including the following: 1. Prespecified research plans, including cohort eligibility, objectives, end points, and analytic plans should be defined a priori. 2. Generalizability requires that the patient sample is broadly representative of patients seen in routine practice, with low attrition, and that the patient data are recent enough that patterns of care have not changed in relevant ways. 3. Data quality requires attention to completeness and validity of end point measures, including predefined rules for capture of structured data and abstraction of unstructured data that may be present in electronic health records. The results of the study by Konishi et al are provocative, with key strengths that include a preplanned analysis and the routinized, guideline-encouraged care provided at a single center. The limitations of this observational study are typical for cohorts of patients treated at a single quaternary care academic institution, including generalizability, potential selection biases, inconsistency in follow-up (might 
